From Zero to 100%: The Pharma Tariff Shock Importers Can't Ignore

For decades, pharmaceutical imports entered the United States essentially duty-free. That era ended on April 2, 2026, when President Trump signed a proclamation slapping tariffs of up to 100% on patented drugs and their ingredients under Section 232. If you import pharmaceuticals — or broker for anyone who does — you have less than four months to figure out a rate structure unlike anything customs has seen before.

Here's a number that should get your attention: the United States imports roughly $200 billion in pharmaceutical products every year. Ireland alone accounts for about $42 billion of that. Switzerland, Germany, India, and Singapore round out the top suppliers. Until last week, nearly all of those imports entered duty-free or at negligible rates.

Now imagine a 100% tariff layered on top. That's not a hypothetical — it's the new default rate for any patented pharmaceutical product that doesn't qualify for one of several reduced-rate tiers. The proclamation creates nine new HTSUS headings (9903.04.60 through 9903.04.69), each with different duty treatment depending on who made the drug, where it was made, and whether the manufacturer has cut a deal with the U.S. government.

This is the first time Section 232 — the national security trade authority traditionally reserved for steel and aluminum — has ever been applied to pharmaceuticals. And it's already reshaping the industry: the White House claims roughly $400 billion in new pharmaceutical investment commitments have materialized in response to the pending tariffs.

What Section 232 Means for Pharma

Section 232 of the Trade Expansion Act of 1962 gives the President authority to impose tariffs on imports that threaten national security. The Commerce Department's investigation concluded that "patented pharmaceuticals and associated pharmaceutical ingredients are being imported into the United States in such quantities and under such circumstances as to threaten to impair our national security."

The logic: while the U.S. dominates pharmaceutical R&D, it has become dangerously dependent on foreign manufacturing. China supplies approximately 17% of active pharmaceutical ingredient (API) imports directly, and India — which provides APIs for roughly 35% of U.S. generic drugs — itself depends on China for about 70% of its bulk drug intermediates. A single supply chain disruption could cut off access to critical medications.

The proclamation's solution is a carrot-and-stick approach: punishing tariffs for companies that keep manufacturing offshore, with steep discounts for those willing to bring production to the United States.

The Tiered Rate Structure: Nine Headings, Nine Different Outcomes

This isn't a simple across-the-board tariff. The proclamation creates a complex matrix of rates that depend on the product, its origin, and whether the manufacturer has entered into agreements with U.S. agencies. Here's how it breaks down:

The difference between classifying under 9903.04.60 (100%) and 9903.04.65 (0%) is, quite literally, the entire cost of the product. Getting the classification right isn't just important — it's existential for margins.

What's Covered — And What's Exempt

Covered products are defined as pharmaceutical articles that meet two criteria: (1) they're subject to a valid, unexpired U.S. patent, and (2) they're listed in the FDA's Orange Book (approved drugs) or Purple Book (licensed biologics). The tariffs also cover associated APIs and key starting materials for those products. The relevant HTS codes span more than 130 subheadings across Chapter 29 (organic chemicals) and Chapter 30 (pharmaceutical products).

Exempt products include:

• Generic pharmaceuticals and biosimilars — not subject to Section 232 tariffs at this time
• U.S.-origin pharmaceutical products, APIs, and materials
• Orphan Drug Act-designated drugs for all approved indications
• Nuclear medicines, plasma-derived therapies, and fertility treatments
• Cell and gene therapies and antibody drug conjugates (ADCs)
• Medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats
• Animal health pharmaceuticals
• Development prototypes under HTSUS code 9817.85.01
• Products listed in Annex IV of the proclamation

That generics exemption comes with a major asterisk: the Commerce Department has one year to reassess whether to extend tariffs to generic pharmaceuticals. If you import generics, don't get too comfortable with that zero rate.

The Onshoring Gambit: 20% Now or 100% Later

The proclamation's most strategically significant provision is the onshoring incentive under heading 9903.04.64. Companies that obtain a Commerce Department-approved plan to move manufacturing to the United States pay just 20% — a steep discount from the 100% default.

But here's the catch: that 20% rate has an expiration date. On April 2, 2030, it jumps to 100%. The message is clear: an onshoring "plan" isn't enough — you need to actually onshore by 2030, or you're back to the full tariff.

For companies considering this route, the clock is ticking on getting Commerce approval. The proclamation directs Commerce to publish Federal Register notices establishing the eligibility criteria and approval process, with a 90-day progress report due to the President.

The MFN Pricing Deal: Zero Tariffs — With Strings Attached

The sweetest deal in the proclamation is heading 9903.04.65: a flat 0% tariff through January 20, 2029. But qualifying requires two simultaneous commitments:

1. A Commerce-approved onshoring plan — same as the 20% tier
2. A Most Favored Nation (MFN) pricing agreement with HHS — meaning U.S. drug prices can't exceed the lowest price offered in comparable countries

Thirteen companies listed in Annex II of the proclamation have already secured this treatment. If your products are manufactured by one of these companies, you may qualify for duty-free entry — but you'll need to verify eligibility against the annex and ensure correct classification.

This dual requirement — onshoring plus pricing — is the administration's attempt to simultaneously address drug costs and manufacturing dependency. Whether pharmaceutical companies will accept MFN pricing constraints for tariff relief is one of the most consequential business decisions in the industry right now.

Key Deadlines Every Importer Must Track

The two-phase rollout is notable: the 17 companies in Annex III — likely the largest pharmaceutical importers — face a 120-day compliance window, while everyone else gets 180 days. If you're not sure whether your suppliers are on the Annex III list, find out immediately.

Classification Challenges: Where HTS Gets Complicated

For customs brokers, this proclamation creates classification headaches that are genuinely unprecedented. You now need to determine, for every pharmaceutical shipment:

1. Is the product patented? Check the FDA Orange Book or Purple Book for patent status. A drug that went generic last month classifies differently from one with a patent expiring next year.

2. Who manufactured it? The rate depends on whether the manufacturer is listed in Annex II (0% MFN deal), Annex III (early effective date), or neither.

3. Where was it made? EU, Japan, South Korea, Switzerland, and Liechtenstein get 15%. The UK gets 10%. Everyone else faces 100% unless they have an agreement.

4. Does it qualify for a specialty exemption? Orphan drugs, cell/gene therapies, and other specialty categories get 0% — but only from jurisdictions with recognized trade frameworks or meeting urgent U.S. health needs.

5. Is the API U.S.-origin? Products made abroad using U.S.-origin APIs may qualify for heading 9903.04.68 at 0%.

One shipment could contain products spanning four or five different rate tiers. And misclassification isn't just a penalty risk — at a 100% tariff rate, the financial exposure for getting it wrong is enormous.

What to Do Right Now: Your Action Plan

1. Map your pharmaceutical portfolio against the annexes. Identify every product you import that could be classified under Chapters 29 or 30. Cross-reference against Annex I (covered products), Annex II (MFN-eligible companies), Annex III (early effective date companies), and Annex IV (exempt products).

2. Verify patent status for every product. Check the FDA Orange Book and Purple Book. A product's tariff rate hinges entirely on whether it holds a valid, unexpired U.S. patent. Build a process to monitor patent expirations — a drug shifting from patented to generic changes its classification overnight.

3. Model your tariff exposure. For each covered product, calculate the applicable Section 232 surcharge on top of the existing HTSUS base rate. A product currently entering at 0% that jumps to 100% will fundamentally change landed cost economics.

4. Confirm origin documentation. The tiered country rates (15% for EU/Japan/Korea/Switzerland/Liechtenstein, 10% for UK) require bulletproof origin records. CBP will be scrutinizing these closely.

5. Review foreign-trade zone strategies. The proclamation requires privileged foreign status for covered goods in FTZs — you can't use zone procedures to avoid the tariff.

6. Engage with Commerce and HHS. If your suppliers aren't on the Annex II or III lists, explore whether onshoring or MFN pricing agreements are viable. The window for negotiations is open now.

7. Set up monitoring for Federal Register notices. Commerce will publish onshoring eligibility criteria, MFN pricing guidance, and specialty product designations in the coming weeks. Missing these could mean missing reduced-rate opportunities.

What's Coming Next

This proclamation is just the opening move. Several developments will reshape the landscape over the coming months:

• Generic reassessment: Commerce has one year to decide whether generics lose their exemption. If tariffs extend to generics, the impact on drug pricing and supply chains would be seismic — India and China dominate generic API supply.

• More Section 232 investigations: The proclamation references ongoing investigations into personal protective equipment, medical consumables, medical devices, and robotics. Pharma tariffs may be the template for a much broader medical supply chain overhaul.

• Drawback eligibility: The proclamation explicitly states that drawback is available for Section 232 pharmaceutical duties. If you're re-exporting covered products, this could offset significant costs.

• Legal challenges: Section 232's application to pharmaceuticals will almost certainly face court challenges. The steel and aluminum tariffs survived legal scrutiny, but extending national security authority to patented drugs is novel legal territory.

Navigating the New Normal

The pharmaceutical tariff regime is the most complex Section 232 action ever issued. Nine different rate tiers, patent-dependent classification, company-specific annexes, country-of-origin differentials, and time-limited agreements — all layered on top of existing HTSUS duties.

The importers and brokers who come through this in good shape will be the ones who start preparing now, not in July when the first deadlines hit. And for those managing large pharmaceutical portfolios, tools like TariffLens that can cross-reference HTS classifications against patent databases and country-of-origin records are about to become indispensable.

This article is for informational purposes only and does not constitute legal, tax, or customs advice. Consult a licensed customs broker or trade attorney for guidance specific to your situation.